Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML | terminated | Phase 1 | 1 | Malika KapadiaOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | terminated | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 6 | Aug 15, 2024 | clinicaltrials |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | terminated | Phase 1 | 71 | Menarini GroupINDUSTRY | 5 | Aug 12, 2024 | clinicaltrials |
| NCT05028751 | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 24 | Kronos BioINDUSTRY | 2 | Aug 7, 2024 | clinicaltrials |
| NCT02091063 | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 23 | Jennifer AmengualOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | terminated | Phase 1 / Phase 2 | 48 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | terminated | Phase 1 | 14 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 68 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | terminated | Phase 1 | 20 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT03318016 | Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 5 | University of Colorado, DenverOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | IGM Biosciences, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02520427 | A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies | terminated | Phase 1 | 95 | AmgenINDUSTRY | 4 | Jul 31, 2024 | clinicaltrials |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03435250 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | terminated | Phase 1 | 123 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 97 | IGM Biosciences, Inc.INDUSTRY | 7 | Jul 24, 2024 | clinicaltrials |
| NCT04305249 | Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies(ERASER) | terminated | Phase 1 | 36 | Antengene Therapeutics LimitedINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04109482 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | terminated | Phase 1 / Phase 2 | 3 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | terminated | Phase 1 / Phase 2 | 20 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | terminated | Phase 1 | 172 | TG Therapeutics, Inc.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | terminated | Phase 1 | 5 | Roncarolo, Maria Grazia, MDOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | terminated | Phase 1 / Phase 2 | 13 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05338346 | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies(ATRIUM) | terminated | Phase 1 | 22 | Antengene Discovery LimitedINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03176277 | A Study of ONO-7475 in Patients With Acute Leukemias | terminated | Phase 1 / Phase 2 | 42 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | terminated | Phase 1 | 85 | CelgeneINDUSTRY | 5 | Jul 9, 2024 | clinicaltrials |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | terminated | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | terminated | Phase 1 / Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | terminated | Phase 1 / Phase 2 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | terminated | Phase 1 | 32 | Cartesian TherapeuticsINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Allogene TherapeuticsINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03451825 | Phase I/II Study of Avelumab in Pediatric Cancer Participants | terminated | Phase 1 | 21 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Jun 24, 2024 | clinicaltrials |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Altor BioScienceINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 38 | TakedaINDUSTRY | 9 | Jun 14, 2024 | clinicaltrials |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | Abdullah KhanOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04172844 | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia(PAVE) | terminated | Phase 1 | 16 | Medical College of WisconsinOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04336982 | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 22 | CelgeneINDUSTRY | 5 | May 31, 2024 | clinicaltrials |
| NCT03175978 | IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 2 | IGF Oncology, LLCINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | terminated | Phase 1 | 37 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 2 | University of ChicagoOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT02663518 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | terminated | Phase 1 | 249 | PfizerINDUSTRY | 2 | May 10, 2024 | clinicaltrials |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04167137 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | terminated | Phase 1 | 32 | SynlogicINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 39 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT00775502 | Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | terminated | Phase 1 | 23 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2024source: clinicaltrials